Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
72.42%
Operating Margin
51.40%
Net Margin
44.76%
Efficiency Metrics
Revenue per Expense Ratio
2.06
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
67.31%
Income Tax Rate
3.31%
EPS
2.0800000000
Balance Sheet Analysis
Current Ratio
1.11
Cash Ratio
0.25
Working Capital
$20.24M
Debt to Equity
0.88
Debt to Assets
43.40%
Equity Ratio
49.52%
Cash Flow Analysis
Operating Cash Flow Ratio
49.64%
Free Cash Flow Ratio
-28.63%
CapEx to Revenue
78.28%
Dividends Paid
$169.37M
Stock Buybacks
$2.51M
Total Shareholder Returns
$171.88M
Cash Position Change
-69.79%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 8.84%
Detailed Growth Metrics
Core Performance
Revenue
13.72%
Net Income
3.05%
EPS
2.97%
Operating Income
49.73%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
9.27%
Operating Cash Flow
-25.82%
Free Cash Flow
373.45%
Balance Sheet Health
Assets
4.47%
Debt
7.55%
Book Value per Share
3.95%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
8.84%
Shares Outstanding
0.18%
Long Term Trends
3Y Revenue/Share
32.33%
5Y Revenue/Share
42.28%
3Y Dividend/Share
28.43%
5Y Dividend/Share
44.58%